این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Research in Pharmaceutical Sciences، جلد ۱۹، شماره ۵، صفحات ۴۸۹-۴۹۹
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Efficacy, safety, and immunogenicity of recombinant insulin aspart (BioGenomics Limited) and NovoRapid® (Novo Nordisk) in adults with type 2 diabetes mellitus: a randomized, open-label, multicenter, phase-3 study
چکیده انگلیسی مقاله Background and purpose: To compare the efficacy, safety, and immunogenicity of recombinant insulin aspart 100 U/mL manufactured by BioGenomics Limited (BGL-ASP) with innovator NovoRapid ® in type 2 diabetes mellitus patients (T2 DM). Experimental approach: This was a multicenter, open-label, randomized, parallel-group study in T2 DM patients, on premix human insulin therapy ± oral anti-diabetics. Besides self‐monitored plasma glucose, fasting and post-prandial plasma glucose (FPG and PPG) were tested at baseline, week 12, and week 24. Anti-insulin aspart antibodies measured immunogenicity at 12 and 24 weeks.  Findings/Results: 160 patients out of 320 patients randomly received BGL-ASP and the remaining patients received NovoRapid ® . The changes in glycated hemoglobin (HbA 1 c) from baseline to weeks 12 and 24 for                       the BGL-ASP group were -0.8 ± 0.83 and -0.8 ± 0.81, respectively, while for the NovoRapid ® group was                  -0.8 ± 1.01 and -0.9 ± 0.89, respectively. Changes in FPG and PPG were comparable between the treatment groups after 12 weeks and 24 weeks. The incidence of detectable antibodies at baseline, weeks 12, and 24 were comparable between treatment groups. Eighteen (11.3%) patients in the BGL-ASP group and 23 (14.4%) in the NovoRapid ® group reported adverse events. Conclusion and implications: BGL-ASP and NovoRapid ® were comparable and equally effective in lowering HbA1c, FPG, and PPG levels, with similar immunogenicity and safety profiles.    
کلیدواژه‌های انگلیسی مقاله Biosimilar,Immunogenicity,Insulin aspart,NovoRapid®,Type 2 diabetes mellitus.
نویسندگان مقاله | Sneha A. Dongre
Clinical Research Department, BioGenomics Ltd., Maharastra, India.


| Gauri A. Kulkarni
Cell Biology Department, BioGenomics Ltd., Maharastra, India.


| Akshay Mishra
Cell Biology Department, BioGenomics Ltd., Maharastra, India.


| Rutuja B. Deshmane
BioGenomics Ltd, Maharastra, India.


| Nameeta Sonar
BioGenomics Ltd, Maharastra, India.


| Kanica Yashi
Molecular Biology Department, BioGenomics Ltd., Maharastra, India.


| Damodar Thapa
Analytical Development, BioGenomics Ltd., Maharastra, India.


| Nikhil Ghade
Clinical Research Department, BioGenomics Ltd., Maharastra, India.


| Sachin M. Kadoo
BioGenomics Ltd, Maharastra, India.


| Archana R. Krishnan
BioGenomics Ltd, Maharastra, India.


| Sanjay M. Sonar


نشانی اینترنتی http://rps.mui.ac.ir/index.php/jrps/article/view/2268
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Original Article
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات